APA način citiranja

Raedler, L. A. (2015). Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits.

Čikaški stil citiranja

Raedler, Lisa A. "Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.

MLA način citiranja

Raedler, Lisa A. "Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.